Deepak L. Bhatt, MD, MPH, FACC

Deepak L. Bhatt, MD, MPH, FACC

General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Elsevier Practice Update Cardiology(SIGNIFICANT), Medtelligence/WebMD(SIGNIFICANT), WebMD(SIGNIFICANT), Level Ex(SIGNIFICANT), K2P(SIGNIFICANT), MJH Life Sciences(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), Piper Sandler(MODEST), Arnold and Porter law firm(SIGNIFICANT), Cowen and Company(MODEST), Wiley(SIGNIFICANT), Oakstone CME(SIGNIFICANT), Broadview Ventures(SIGNIFICANT), McKinsey(SIGNIFICANT) EQUITY INTERESTS/STOCK OPTIONS: DRS.LINQ(SIGNIFICANT), AngioWave(SIGNIFICANT), High Enroll(SIGNIFICANT), Bristol-Myers Squibb Company (SIGNIFICANT) OFFICER, DIRECTOR ETC: TobeSoft(SIGNIFICANT), DRS.LINQ(SIGNIFICANT), AngioWave(SIGNIFICANT), High Enroll(SIGNIFICANT), Bristol-Myers Squibb Company (SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Eisai(SIGNIFICANT), FlowCo(NONE), Roche(SIGNIFICANT), Sanofi Aventis(SIGNIFICANT), Bristol Myers Squibb(SIGNIFICANT), Takeda(NONE), Pfizer Inc(SIGNIFICANT), Forest Laboratories(SIGNIFICANT), Amarin(SIGNIFICANT), Astra Zeneca(SIGNIFICANT), Medtronic(SIGNIFICANT), Ethicon(SIGNIFICANT), Ischemix(SIGNIFICANT), The Medicines Company(SIGNIFICANT), Amgen Inc.(SIGNIFICANT), Chiesi(SIGNIFICANT), Eli Lilly and Company(SIGNIFICANT), Ironwood(SIGNIFICANT), Abbott(SIGNIFICANT), Regeneron(SIGNIFICANT), PhaseBio(SIGNIFICANT), Idorsia(SIGNIFICANT), Synaptic(SIGNIFICANT), Afimmune(SIGNIFICANT), Fractyl(SIGNIFICANT), PLx Pharma(SIGNIFICANT), Lexicon(SIGNIFICANT), Bayer Healthcare Pharmaceuticals(SIGNIFICANT), Cardax(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(SIGNIFICANT), MyoKardia(SIGNIFICANT), Owkin(SIGNIFICANT), HLS Therapeutics(SIGNIFICANT), 89Bio(SIGNIFICANT), Garmin(SIGNIFICANT), Novartis(SIGNIFICANT), NirvaMed(SIGNIFICANT), Janssen Pharmaceuticals, Inc(SIGNIFICANT), Stasys(SIGNIFICANT), Faraday(SIGNIFICANT), Aker Biomarine(SIGNIFICANT), Recardio(SIGNIFICANT), Beren(SIGNIFICANT), Moderna(SIGNIFICANT), CinCor(SIGNIFICANT), Youngene(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Merck & Co., Inc.(NONE), Journal of Invasive Cardiology(SIGNIFICANT), Belvoir Publications(SIGNIFICANT), Clinical Cardiology(NONE), Slack Publications/Cardiology Research Foundation(SIGNIFICANT), HMP Global(SIGNIFICANT), Janssen Pharmaceuticals, Inc(MODEST), Novo Nordisk Inc.(MODEST), MyoKardia(SIGNIFICANT), CellProthera(SIGNIFICANT), Cereno Scientific(SIGNIFICANT), Cardax(SIGNIFICANT), PLx Pharma(SIGNIFICANT), Elsevier(SIGNIFICANT), PhaseBio(SIGNIFICANT), NirvaMed(SIGNIFICANT), Medscape Cardiology(NONE), Regado Biosciences(NONE), Stasys(SIGNIFICANT), Bayer Healthcare Pharmaceuticals(SIGNIFICANT), Merck(MODEST), Lexicon(NONE)

View Full Disclosure